Fundraising FoxKiwoom Investment — 2025 Investments
4 investments dated 2025 · listed companies and verified rows first · show all
DD Pharmatech develops therapeutics for metabolic disorders, with a focus on oral and long-acting GLP-1 receptor agonist formulations.
Biotech
Seulki Lee(Executive Officer, Director)inSunghoon Hong(Executive Officer, Director)Sungmook Lim(Executive Officer, Director)
BoardDaehyun Shin(Director)Seungwon Lim(Director)Seol-Heui Han(Director)
Co-investorsDAYLI PartnersLB InvestmentMagna InvestmentOctave Ventures Llc
Datumo Eval is an LLM evaluation platform that generates industry-specific question datasets from source documents and assesses LLM models and LLM-powered services using default or custom metrics via an agentic flow of multiple LLM agents.
AI & Machine LearningCybersecurityData & InfrastructureDeveloper Tools
Michael Hwang(Founder)inMichael (Minyoung) Hwang(Founder)inHawk Shin(Co-Founder)David Kim(Chief Executive Officer (CEO))inDavid J. Kim(Founder)
Co-investorsACVC PartnersSalesforce VenturesKB InvestmentSBI InvestmentShinhan Venture Investment
Korean aesthetic-medicine platform, operated by Healing Paper, connecting users with clinics for treatment information and bookings.
Co-investorsAtinum Investment Co. Ltd.KT investment Inc.KT Strategic Investment Fund 4Aju IB InvestmentDSC InvestmentIMM Investment+4 more
Prazer Therapeutics develops therapeutics using Targeted Protein Degradation (TPD) technology, including its SPiDEM platform, in which small molecules selectively bind pathological proteins and activate the ubiquitin-proteasome system for their elimination.
BiotechDeep TechSeoul, KR
Co-investorsPremier PartnersCompany K PartnersSmilegate Investment
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.